Jan. 27, 2009 Simple aspirin may prevent liver damage in millions of people suffering from side effects of common drugs, alcohol abuse, and obesity-related liver disease, a new Yale University study suggests.
The study documents that in mice, aspirin reduced mortality caused by an overdose of acetaminophen, best known by the brand name Tylenol. It further showed that a class of molecules known as TLR antagonists, which block receptors known to activate inflammation, have a similar effect as aspirin.
Since these agents seem to work by reducing injury-induced inflammation, the results suggest aspirin may help prevent and treat liver damage from a host of non-infectious causes, said Wajahat Mehal, M.D., of the Section of Digestive Diseases and Department of Immunobiology at Yale School of Medicine.
"Many agents such as drugs and alcohol cause liver damage, and we have found two ways to block a central pathway responsible for such liver injury," Mehal said. "Our strategy is to use aspirin on a daily basis to prevent liver injury, but if it occurs, to use TLR antagonists to treat it."
Promising drugs that have failed clinical trials because of liver toxicity might be resurrected if combined with aspirin, Mehal said.
"This offers the exciting possibility of reducing a lot of pain and suffering in patients with liver diseases, using a new and very practical approach," Mehal said.
Other researchers from Yale who contributed to this study are Avlin Imaeda, Azuma Watanabe, Adnan Sohail, Shamail Mahmood, Mehdi Mohamadnejad, Fayyaz Sutterwala, and Richard Flavell.
The National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health, the Ellison Foundation, and the Howard Hughes Medical Institute funded the study.
Other social bookmarking and sharing tools:
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
- Imaeda et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the
Nalp3 inflammasome. Journal of Clinical Investigation, Jan 26, 2009; DOI: 10.1172/JCI35958
Note: If no author is given, the source is cited instead.